Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Language
Publication year range
1.
Clin Transl Oncol ; 14(5): 350-5, 2012 May.
Article in English | MEDLINE | ID: mdl-22551540

ABSTRACT

PURPOSE: To assess the results of I-125 episcleral brachytherapy (EB) in uveal melanoma: tumour control, visual acuity (VA), eye preservation and survival. PATIENTS: Prospective and consecutive study of patients with a diagnosis of uveal melanoma at the Ocular Oncology Unit in the Valladolid University Teaching Hospital treated with EB between September 1997 and June 2008. Ocular examination and extraocular and systemic extension data were registered in a database at the time of the diagnosis and during the follow-up. RESULTS: Among a total of 310 patients diagnosed between September 1997 and June 2008, 136 were treated with EB (mean age, 58.3). Mean follow-up was 55.3 months. As for tumour type, 66.9% were nodular and 39% mushroom shaped. With respect to size, 80.9% were medium, 7.4% small and 11.8% large. After 4.6 years of follow-up, tumours were controlled in 97.1%, with a 55.1% reduction in mean height; only 2.9% of patients showed recurrence. VA was maintained in 16.2% of patients and 17.6% showed an increase; 33% had retinopathy and 14.6% optic neuropathy. Only 5.1% of patients underwent enucleation due to complications and there has been 1 melanoma-related death to date. CONCLUSIONS: I-125 EB is effective in tumour control, allowing preservation of the eye and useful visual function for the majority of patients.


Subject(s)
Brachytherapy , Eye Neoplasms/radiotherapy , Iodine Radioisotopes/therapeutic use , Melanoma/radiotherapy , Scleral Diseases/radiotherapy , Uveal Neoplasms/radiotherapy , Eye Enucleation , Eye Neoplasms/mortality , Eye Neoplasms/pathology , Female , Follow-Up Studies , Humans , Male , Melanoma/mortality , Melanoma/pathology , Middle Aged , Neoplasm Staging , Scleral Diseases/mortality , Scleral Diseases/pathology , Survival Rate , Treatment Outcome , Uveal Neoplasms/mortality , Uveal Neoplasms/pathology , Visual Acuity/radiation effects
2.
Clin. transl. oncol. (Print) ; 14(5): 350-355, mayo 2012. tab, ilus
Article in English | IBECS | ID: ibc-126908

ABSTRACT

PURPOSE: To assess the results of I-125 episcleral brachytherapy (EB) in uveal melanoma: tumour control, visual acuity (VA), eye preservation and survival. PATIENTS: Prospective and consecutive study of patients with a diagnosis of uveal melanoma at the Ocular Oncology Unit in the Valladolid University Teaching Hospital treated with EB between September 1997 and June 2008. Ocular examination and extraocular and systemic extension data were registered in a database at the time of the diagnosis and during the follow-up. RESULTS: Among a total of 310 patients diagnosed between September 1997 and June 2008, 136 were treated with EB (mean age, 58.3). Mean follow-up was 55.3 months. As for tumour type, 66.9% were nodular and 39% mushroom shaped. With respect to size, 80.9% were medium, 7.4% small and 11.8% large. After 4.6 years of follow-up, tumours were controlled in 97.1%, with a 55.1% reduction in mean height; only 2.9% of patients showed recurrence. VA was maintained in 16.2% of patients and 17.6% showed an increase; 33% had retinopathy and 14.6% optic neuropathy. Only 5.1% of patients underwent enucleation due to complications and there has been 1 melanoma-related death to date. CONCLUSIONS: I-125 EB is effective in tumour control, allowing preservation of the eye and useful visual function for the majority of patients (AU)


Subject(s)
Humans , Male , Female , Middle Aged , Brachytherapy/methods , Brachytherapy , Melanoma/mortality , Uveal Neoplasms/pathology , Scleral Diseases/pathology , Iodine Radioisotopes/therapeutic use , Melanoma/radiotherapy , Scleral Diseases/radiotherapy , Uveal Neoplasms/radiotherapy , Eye Enucleation/methods , Eye Enucleation , Follow-Up Studies , Melanoma/pathology , Neoplasm Staging , Scleral Diseases/mortality , Survival Rate , Treatment Outcome , Uveal Neoplasms/mortality , Visual Acuity/radiation effects
3.
Arch Ophthalmol ; 127(8): 1006-10, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19667337

ABSTRACT

OBJECTIVE: To describe the clinical and pathological features of patients with retinoblastoma and microscopic scleral invasion. METHODS: We reviewed all pathology slides of patients with microscopic scleral invasion who were included in 3 prospective treatment protocols (1988-2007). All patients received adjuvant chemotherapy (moderately intensive chemotherapy in the first 2 protocols or a more intensive combination in the third one). Only patients with cut-end invasion received orbital radiotherapy. RESULTS: Thirty-two of 386 patients had enucleated eyes with intrascleral (21 cases) and transscleral (11 cases) invasion. Of these cases, 20 had tumor invading the optic nerve beyond the lamina cribrosa, with 6 of these having tumor at the surgical margin. Sixteen were treated with moderately intensive chemotherapy and 16 received a higher-intensity regimen. Five-year overall survival was 0.77. Seven patients had an extraocular relapse (central nervous system metastasis, n = 4; systemic metastasis, n = 2; and involving the orbit, n = 3, isolated in 1 and combined with central nervous system disease in 2). All patients who had a relapse died. Patients receiving the intensive regimen had a significantly better outcome (P = .007). CONCLUSIONS: Microscopic scleral invasion might be a risk factor for extraocular relapse, and more intensive chemotherapy results in improved survival for these patients.


Subject(s)
Eye Neoplasms/pathology , Neoplasm Recurrence, Local/pathology , Retinal Neoplasms/pathology , Retinoblastoma/pathology , Scleral Diseases/pathology , Chemotherapy, Adjuvant , Child , Child, Preschool , Eye Enucleation , Eye Neoplasms/drug therapy , Eye Neoplasms/mortality , Female , Follow-Up Studies , Humans , Infant , Male , Neoplasm Invasiveness , Prospective Studies , Retinal Neoplasms/drug therapy , Retinal Neoplasms/mortality , Retinoblastoma/drug therapy , Retinoblastoma/mortality , Scleral Diseases/drug therapy , Scleral Diseases/mortality , Survival Rate
4.
Can J Ophthalmol ; 39(4): 380-7, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15327103

ABSTRACT

BACKGROUND: Currently available clinical information regarding management of posterior uveal melanomas complicated by nodular extrascleral extension is inadequate to determine the role, if any, for plaque radiotherapy in such patients. METHODS: The authors performed a retrospective descriptive study of eight patients with a choroidal or ciliochoroidal melanoma complicated by nodular extrascleral extension who were treated by surgical excision of the extrascleral nodule followed immediately by plaque radiotherapy of the intraocular tumour. The calculated volume of the extrascleral nodule was greater than 1 mm3 but less than 1000 mm3 in all cases, and the intraocular tumour was deemed treatable by plaque radiotherapy in all patients. RESULTS: Four of the eight patients died during available follow-up, three from metastatic melanoma and one from a second cancer. The median length of follow-up for the four surviving patients was 10.1 years. The actuarial 5-year and 10-year all-cause death rates were 37.5% and 53.1% respectively. One of the eight patients experienced local intraocular tumour relapse following plaque therapy and underwent secondary enucleation. None of the patients experienced orbital tumour recurrence or underwent secondary orbital exenteration. INTERPRETATION: Our results coupled with previously published results from another centre suggest that plaque radiotherapy may be an effective local treatment for selected patients with choroidal or ciliochoroidal melanoma complicated by nodular extrascleral extension. The fact that none of the patients in this series or in the previously reported series experienced orbital recurrence following plaque radiotherapy or required secondary orbital exenteration suggests that plaque therapy may be better than enucleation alone in terms of these end points. These results should not be extrapolated, of course, to patients with massive extrascleral tumour extension or a choroidal or ciliochoroidal melanoma too large for plaque radiotherapy.


Subject(s)
Brachytherapy/methods , Choroid Neoplasms/radiotherapy , Ciliary Body/radiation effects , Eye Neoplasms/radiotherapy , Melanoma/radiotherapy , Scleral Diseases/radiotherapy , Aged , Choroid Neoplasms/mortality , Choroid Neoplasms/pathology , Ciliary Body/pathology , Eye Neoplasms/mortality , Eye Neoplasms/secondary , Female , Humans , Male , Melanoma/mortality , Melanoma/secondary , Middle Aged , Neoplasm Invasiveness , Retrospective Studies , Sclera/pathology , Scleral Diseases/mortality , Survival Rate , Uveal Neoplasms/mortality , Uveal Neoplasms/pathology , Uveal Neoplasms/radiotherapy
SELECTION OF CITATIONS
SEARCH DETAIL
...